Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program
Francesco Passiglia, Maria Lucia Reale, Giuseppe Lo Russo, et al.
Lung Cancer (2023) Vol. 187, pp. 107444-107444
Open Access | Times Cited: 12

Showing 12 citing articles:

Hepatobiliary Adverse Events Associated With the KRAS p.G12C Inhibitor Sotorasib
Connor Frey
Pharmacoepidemiology and Drug Safety (2025) Vol. 34, Iss. 2
Open Access | Times Cited: 1
Treatment patterns and outcomes in KRAS‐positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study
Samir H. Barghout, Luna Jia Zhan, Starvroula Raptis, et al.
Lung Cancer (2024) Vol. 194, pp. 107898-107898
Closed Access | Times Cited: 6
Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: the IFCT-2102 Lung KG12Ci study
Marie Wislez, Céline Mascaux, J. Cadranel, et al.
European Journal of Cancer (2025) Vol. 219, pp. 115301-115301
Open Access
Reducing pERKs to Break “RAS”istance to Sotorasib
Steven G. Gray, Derbrenn O'Connor, Luciano Mutti, et al.
Journal of Thoracic Oncology (2025) Vol. 20, Iss. 3, pp. 259-261
Closed Access
Second-line therapy for KRAS-positive metastatic non-small cell lung cancer
Martin Svatoň
Onkologie (2025) Vol. 19, Iss. 1, pp. 29-32
Closed Access
Advances in the treatment of KRASG12C mutant non–small cell lung cancer
Khvaramze Shaverdashvili, Timothy F. Burns
Cancer (2025) Vol. 131, Iss. S1
Open Access
Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal
Ali Chour, Clémence Basse, Fanny Lebossé, et al.
Lung Cancer (2024) Vol. 191, pp. 107789-107789
Closed Access | Times Cited: 3
CodeBreak 200: study limitations, and future directions
Malak Alharbi, Muhammad Awidi, Grace K. Dy
Translational Cancer Research (2024) Vol. 13, Iss. 1, pp. 15-21
Open Access | Times Cited: 2
Real-World Evaluation of Treatment Patterns, Healthcare Costs, and Healthcare Resource Utilization Among Patients with Non-small Cell Lung Cancer in the US Receiving Sotorasib
Ihtisham Sultan, David Waterhouse, Divyan Chopra, et al.
Advances in Therapy (2024) Vol. 41, Iss. 12, pp. 4648-4659
Open Access | Times Cited: 2
Real-world comparative effectiveness of sotorasib versus docetaxel in second line and beyond among patients with advanced non-small cell lung cancer (NSCLC)
Melissa L. Johnson, Diana Younan, Shia T. Kent, et al.
Lung Cancer (2024) Vol. 197, pp. 107960-107960
Open Access | Times Cited: 1
Hepatitis associated with immune checkpoint inhibitors-based combinations of other therapies: A real-world pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database
Zhaohui Li, Zixiang Zhou, Nan Zhang, et al.
Cancer Immunology Immunotherapy (2024) Vol. 74, Iss. 1
Open Access | Times Cited: 1
A Response to the Letter to the Editor: Comment on “Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib”
Sophie M. Ernst, Jan H. von der Thüsen, Hendrikus J. Dubbink, et al.
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 9, pp. e44-e45
Closed Access
Page 1

Scroll to top